COST EFFECTIVENESS OF ZOLEDRONIC ACID VS. PAMIDRONATE OR NO THERAPY FOR THE TREATMENT OF BONE METASTASES SECONDARY TO PROSTATE CANCER

被引：0
|
作者：
Carter, J. A. [1 ]
Bains, M. [2 ]
Chandiwana, D. [2 ]
Kaura, S. [3 ]
Botteman, M. F. [1 ]
机构：
[1] Pharmerit N Amer LLC, Bethesda, MD USA
[2] Novartis Pharmaceut UK Ltd, Camberley, Surrey, England
[3] Novartis Pharmaceut, Florham Pk, NJ USA
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1174
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A447 / A447
页数：1
相关论文
共 50 条
  • [41] A COMPARISON OF THE COST-EFFECTIVENESS OF ZOLEDRONIC ACID FOR PREVENTING SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES FROM PROSTATE CANCER IN 4 EUROPEAN COUNTRIES
    Botteman, M.
    Carter, J.
    Kaura, S.
    VALUE IN HEALTH, 2010, 13 (07) : A264 - A264
  • [42] Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer
    Van Poznak, Catherine H.
    Unger, Joseph M.
    Darke, Amy K.
    Moinpour, Carol
    Bagramian, Robert A.
    Schubert, Mark M.
    Hansen, Lisa Kathryn
    Floyd, Justin D.
    Dakhil, Shaker R.
    Lew, Danika L.
    Wade, James Lloyd, III
    Fisch, Michael J.
    Henry, N. Lynn
    Hershman, Dawn L.
    Gralow, Julie
    JAMA ONCOLOGY, 2021, 7 (02) : 246 - 254
  • [43] The role of zoledronic acid in cancer: Clinical studies in the treatment and prevention of bone metastases
    Coleman, RE
    Seaman, JJ
    SEMINARS IN ONCOLOGY, 2001, 28 (02) : 11 - 16
  • [44] Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases
    Ibrahim, A
    Scher, N
    Williams, G
    Sridhara, R
    Li, N
    Chen, G
    Leighton, J
    Booth, B
    Gobburu, JVS
    Rahman, A
    Hsieh, Y
    Wood, R
    Vause, D
    Pazdur, R
    CLINICAL CANCER RESEARCH, 2003, 9 (07) : 2394 - 2399
  • [45] A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease
    Liana DesHarnais Castel
    Kamila Bajwa
    Justin P. Markle
    Justin W. Timbie
    Christopher Zacker
    Kevin A. Schulman
    Supportive Care in Cancer, 2001, 9 : 545 - 551
  • [46] Zoledronic acid in lung cancer with bone metastases: a review
    Isla, Dolores
    Afonso, Ruth
    Bosch-Barrera, Joaquim
    Martinez, Natividad
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (04) : 421 - 426
  • [47] A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease
    Castel, LD
    Bajwa, K
    Markle, JP
    Timbie, JW
    Zacker, C
    Schulman, KA
    SUPPORTIVE CARE IN CANCER, 2001, 9 (07) : 545 - 551
  • [48] CANCER Breast cancer bone metastases: denosumab or zoledronic acid?
    van der Pluijm, Gabri
    NATURE REVIEWS ENDOCRINOLOGY, 2011, 7 (03) : 134 - 135
  • [49] COST-EFFECTIVENESS OF DENOSUMAB VS. ZOLEDRONIC ACID IN A POPULATION 75 YEARS OR OLDER IN THE US
    Stolshek, Brad
    Kruse, Morgan
    Yurgin, Nicole
    Huang, Joice
    Ho, Pei-Ran
    Wang, Andrea
    Parthan, Anju
    Taylor, Doug
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 : S137 - S138
  • [50] Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer
    Reed, SD
    Radeva, JI
    Glendenning, GA
    Saad, F
    Schulman, KA
    JOURNAL OF UROLOGY, 2004, 171 (04) : 1537 - 1542
12345